Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA has approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after radical cystectomy, for adults with muscle-invasive bladder cancer.
Efficacy was evaluated in NIAGARA (ClinicalTrials.gov Identifier: NCT03732677), a randomized, open-label, multicenter, phase 3 trial enrolling 1,063